Technical Analysis for HOOK - HOOKIPA Pharma Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Historical HOOK trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| Jack-in-the-Box Bullish | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 15 hours ago |
| Possible Inside Day | about 15 hours ago |
| Down 3% | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 17 hours ago |
| Down 2 % | about 17 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/12/2021
HOOKIPA Pharma Inc. Description
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Cancers Hepatitis B Transplantation Immunodeficiency Hepatitis B Virus Viral Disease Gilead Sciences Papillomavirus Immunotherapeutics Kidney Transplant
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.7502 |
| 52 Week Low | 8.12 |
| Average Volume | 211,880 |
| 200-Day Moving Average | 11.40 |
| 50-Day Moving Average | 13.29 |
| 20-Day Moving Average | 13.71 |
| 10-Day Moving Average | 15.09 |
| Average True Range | 1.00 |
| ADX | 27.6 |
| +DI | 31.40 |
| -DI | 9.67 |
| Chandelier Exit (Long, 3 ATRs ) | 14.75 |
| Chandelier Exit (Short, 3 ATRs ) | 14.60 |
| Upper Bollinger Band | 16.90 |
| Lower Bollinger Band | 10.52 |
| Percent B (%b) | 0.99 |
| BandWidth | 46.56 |
| MACD Line | 0.93 |
| MACD Signal Line | 0.53 |
| MACD Histogram | 0.4003 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.15 | ||||
| Resistance 3 (R3) | 19.16 | 18.41 | 18.76 | ||
| Resistance 2 (R2) | 18.41 | 17.82 | 18.40 | 18.64 | |
| Resistance 1 (R1) | 17.62 | 17.45 | 18.01 | 17.61 | 18.51 |
| Pivot Point | 16.87 | 16.87 | 17.06 | 16.86 | 16.87 |
| Support 1 (S1) | 16.08 | 16.28 | 16.48 | 16.07 | 15.17 |
| Support 2 (S2) | 15.33 | 15.91 | 15.32 | 15.04 | |
| Support 3 (S3) | 14.54 | 15.33 | 14.92 | ||
| Support 4 (S4) | 14.53 |
